Regulus Reports Third Quarter 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Regulus Therapeutics (RGLS) Tops Q3 EPS by 12c
November 6, 2015 8:23 AM ESTRegulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.85 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More